Abstract
Abstract
Background
Herbs are commonly used to treat cardiovascular diseases in various traditional medicine. On the other hand, herb-drug interactions are most commonly encountered with conventional antiplatelet and anticoagulant drug prescriptions. This review presents a compilation of plants investigated for antiplatelet and anticoagulation recently and enumerates their possible lead compounds responsible for its action for paving further drug discovery and knowledge update.
Main body of the abstract
Information about the herbs was withdrawn from the PubMed database of the previous 5 years. We also hand-searched the bibliography of relevant articles for the acquisition of additional information. About 72 herbal sources were identified with the effect of antiplatelet activity, antithrombotic activity, and anticoagulant activity. Bioactive compounds and various secondary metabolites responsible for it, such as alkaloids, saponins, flavonoids, coumarins, polyphenols, furan derivatives, iridoid glycosides, sesquiterpenes, aporphine compounds, were reported.
Conclusion
Newer pharmacological moieties are needed to prevent or reduce the adverse effects of current anti-thrombotic agents and to improve the safety of patients and cost-effectiveness.
Publisher
Springer Science and Business Media LLC
Reference111 articles.
1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP et al (2019) Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 139(10):e56–e528 Available from: http://ahajournals.org [cited 10 Apr 2021]
2. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP et al (2020) Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation 141:E139–E596 Available from: http://ahajournals.org Lippincott Williams and Wilkins; [cited 10 Apr 2021]
3. Singhania N, Bansal S, Nimmatoori DP, Ejaz AA, McCullough PA, Singhania G (2020) Current overview on hypercoagulability in COVID-19. Am J Cardiovasc Drugs. 20(5):393–403 Available from: /pmc/articles/PMC7398761/ [cited 10 Apr 2021]
4. Klok F, Kruip M, van der Meer N, Arbous M, Gommers D, Kant K et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. https://doi.org/10.1016/j.thromres.2020.04.013 [cited 10 Apr 2021]
5. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X et al (2020) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 46(6):1089–1098. https://doi.org/10.1007/s00134-020-06062-x [cited 10 Apr 2021]
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献